References:
1. Anonymous. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Part 7. Stratification of risk for progression of kidney disease and development of cardiovascular disease. Guideline 15. Association of chronic kidney disease with cardiovascular disease http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p7_risk_g15.htm
2.Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:112-119, 1998
3.Lee CY, Pellikka PA, Shub C, Sinak LJ, Seward JB. Hypertensive response during dobutamine stress echocardiography. Am J Cardiol. 1997 Oct 1;80(7):970-1.
4.Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging J Am Soc Echocardiogr. 2015 ;28:1-39
5.Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. American Society of Echocardiography; European Association of Echocardiography. American Society of Echocardiography; European Association of Echocardiography. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr. 2009;22:1-23.
6.Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, et al. American Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16:777-802.
7. Pellikka PA, Arruda-Olson A, Chaudhry FA, Chen MH, Marshall JE, Porter TR, Sawada SG.
Guidelines for Performance, Interpretation, and Application of Stress Echocardiography in Ischemic Heart Disease: From the American Society of Echocardiography. J Am Soc Echocardiogr. 2020 Jan;33(1):1-41
8. Hannan EL, Racz M, Holmes DR, King SB III., Walford G, Ambrose JA, et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation. 2006;113:2406–2412.
9.Geleijnse ML, Krenning BJ, Nemes A, van Dalen BM, Soliman OI, Ten Cate FJ, et al. Incidence, pathophysiology, and treatment of complications during dobutamine-atropine stress echocardiography. Circulation. 2010; 121:1756-67.
10.Secknus MA, Marwick TH. Evolution of dobutamine echocardiography protocols and indications: safety and side effects in 3,011 studies over 5 years. J Am Coll Cardiol. 1997; 29:1234-40.
11.San Román JA, Sanz-Ruiz R, Ortega JR, Pérez-Paredes M, Rollán MJ, Muñoz AC, et al. Safety and predictors of complications with a new accelerated dobutamine stress echocardiography protocol. J Am Soc Echocardiogr. 2008;21:53-7.
12.Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912-8.
13.Campese VM, Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep. 2002;4:256-60.
14.Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis. 1997; 29:2-26.’
15.Weidmann P, Maxwell MH, Lupu AN, Lewin AJ, Massry SG. Plasma renin activity and blood pressure in terminal renal failure. N Engl J Med. 1971;285:757-62.
16.Zucchelli P, Zuccala A, Sturani A, Degli Esposti E, Ligabue A, Santoro A, et al. Hypertension in end-stage renal failure: role of sympathetic nervous system, sodium balance and renal pressor system. Life Support Syst. 1983;1:101-11.
17.Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis. 2001;38 (Suppl 1):S74-9.
18.Barenbrock M, Spieker C, Laske V, Baumgart P, Hoeks AP, Zidek W, et al. Effect of long-term hemodialysis on arterial compliance in end-stage renal failure. Nephron. 1993;65:249-53.
19.London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int. 1996;50:600-8.
20.Sutliff RL, Walp ER, El-Ali AM, Elkhatib S, Lomashvili KA, O’Neill WC. Effect of medial calcification on vascular function in uremia. Am J Physiol Renal Physiol. 2011; 301:F78-83.
21.Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol. 2008;294:F1-9.
22.Barenbrock M, Hausberg M, Kosch M, Kisters K, Hoeks AP, Rahn KH. Effect of hyperparathyroidism on arterial distensibility in renal transplant recipients. Kidney Int. 1998;54:210-5.
23.Gottdiener JS, Brown J, Zoltick J, Fletcher RD. Left ventricular hypertrophy in men with normal blood pressure: relation to exaggerated blood pressure response to exercise. Ann Intern Med. 1990;112:161-6.
24.Ha JW, Juracan EM, Mahoney DW, Oh JK, Shub C, Seward JB, et al. Hypertensive response to exercise: a potential cause for new wall motion abnormality in the absence of coronary artery disease. J Am Coll Cardiol. 2002;39:323-7.
25.Sawada SG. Dobutamine stress echocardiography: Causes and approach to false negative and false positive studies. ACC Current Journal Review 1995;4:34-38.
26.McNeill AJ, Fioretti PM, el-Said SM, Salustri A, Forster T, Roelandt JR. Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dobutamine stress echocardiography. Am J Cardiol. 1992;70:41-6.
27. Aggeli C, Giannopoulos G, Roussakis G, Christoforatou E, Marinos G, Toli C, et al. Safety of myocardial flash-contrast echocardiography in combination with dobutamine stress testing for the detection of ischemia in 5250 studies. Heart. 2008;94:1571-7.
28.Bybee KA, Prasad A. Stress-related cardiomyopathy syndromes. Circulation. 2008; 118:397-409.